SPERO BIOPHARMA
Committed to the Transforming Chronic Disease
BACKGROUND
Spero Biopharma Ltd. was founded by Prof. Marta Weinstock-Rosin, a world-renowned inventor and researcher who invented Exelon®, a blockbuster drug for the treatment of Alzheimer’s disease. Prof Weinstock-Rosin is professor emeritus at the Hebrew University’s School of Pharmacy-Institute for Drug Research in the Faculty of Medicine.
WHAT WE DO
Spero Biopharma’s leading compounds include SPE-100, an innovative treatment for Mild Cognitive Impairment (MCI) which has completed Phase 2 and SPE-200 for NASH.
SPE-100
provides neuro-protection including by the reduction of microglialactivation and inhibition of pro-inflammatory cytokines
Has a rich body of preclinical and clinical data
SP-100 has completed a multinational phase-II trial in MCI with positive final results
SPE-200 has rich pre-clinical data and is ready to proceed to Phase 1
Spero has a leading team including world class founders and advisory board
Broad IP coverage
"Big results require big ambitions"